Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab after split course chemoradiation in elderly or poor risk stage III NSCLC
NCT04441138Phase 2Terminated
- Sponsor
- Rush University Medical Center
- Start
- Feb 2021
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Rush University Medical Center. Primary endpoints: Rate of Split Course Chemoradiation Completion at 3 months and Number of Cycles of Durvalumab (MEDI4736) Received at 1 year. Started Feb 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04441138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441138.